Alvotech (ALVO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Alvotech stock (ALVO) is currently trading at $3.13. Alvotech PE ratio is 15.35. Alvotech PS ratio (Price-to-Sales) is 1.92. Analyst consensus price target for ALVO is $15.50. WallStSmart rates ALVO as Sell.
- ALVO PE ratio analysis and historical PE chart
- ALVO PS ratio (Price-to-Sales) history and trend
- ALVO intrinsic value — DCF, Graham Number, EPV models
- ALVO stock price prediction 2025 2026 2027 2028 2029 2030
- ALVO fair value vs current price
- ALVO insider transactions and insider buying
- Is ALVO undervalued or overvalued?
- Alvotech financial analysis — revenue, earnings, cash flow
- ALVO Piotroski F-Score and Altman Z-Score
- ALVO analyst price target and Smart Rating
Alvotech
📊 No data available
Try selecting a different time range
ALVO Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Alvotech (ALVO)
ALVO trades 211% above its Graham fair value of $1.56, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Alvotech (ALVO) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales. Concerns around operating margin and eps growth. Significant fundamental concerns warrant caution or avoidance.
Alvotech (ALVO) Key Strengths (1)
Paying $1.92 for every $1 of annual revenue
Supporting Valuation Data
Alvotech (ALVO) Areas to Watch (6)
Losing money on operations
Earnings declining -58.40%, profits shrinking
Very low institutional interest at 6.08%
Small-cap company with higher risk but more growth potential
Solid revenue growth at 10.60% per year
Decent profitability, keeps $12 per $100 revenue
Alvotech (ALVO) Detailed Analysis Report
Overall Assessment
This company scores 27/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 3.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales. Valuation metrics including Price/Sales (1.92) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Operating Margin, EPS Growth, Institutional Own.. Growth concerns include Revenue Growth at 10.60%, EPS Growth at -58.40%, which may limit upside. Profitability pressure is visible in Operating Margin at -2.62%, Profit Margin at 12.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -2.62% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 10.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ALVO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ALVO's Price-to-Sales ratio of 1.92x trades at a deep discount to its historical average of 30.22x (2th percentile). The current valuation is 98% below its historical high of 84.74x set in Dec 2022, and 2% above its historical low of 1.89x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~6.1x as trailing revenue scaled faster than the stock price.
Compare ALVO with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Alvotech (ALVO) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Alvotech operates as a stable business with moderate growth and solid fundamentals. Revenue reached 573M with 11% growth year-over-year. Profit margins of 12.1% are healthy, with room for further expansion as the business scales.
Key Findings
Debt-to-equity ratio of -7.25 indicates a conservative balance sheet with 43M in cash.
Free cash flow is -75M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
Earnings fell 58% YoY while revenue grew 11%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Margin expansion: can Alvotech push profit margins above 15% as the business scales?
Debt management: total debt of 1.3B is significantly higher than cash (43M). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Alvotech.
Bottom Line
Alvotech offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Alvotech(ALVO)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.